Zacks Investment Research Initiated Coverage on LED Medical Diagnostics with Outperform Rating - Video Research Alert on InvestmentPitch.com

Vancouver, British Columbia--(Newsfile Corp. - January 23, 2014) - Zacks Investment Research has initiated coverage on LED Medical Diagnostics (TSXV: LMD) (OTCQX: LEDIF). Analyst Brian Marckx gives the company an outperform rating and a $2.00 target price, a premium of 308% over the $0.49 price on January 21st, the day the report was issued.

InvestmentPitch.com has produced a "video research alert" about LED Medical based on this report. If this link is not enabled, please visit www.InvestmentPitch.com and enter "LED Medical" in the search box.

If you cannot view the video above, please visit:
http://www.investmentpitch.com/video/0_yud4celj/Zacks-Investment-Research-Initiates-Coverage-on-LED-Medical-Diagnostics-with-Outperform-Rating

LED Medical Diagnostics develops LED-based visualization technologies for the medical industries. The company's VELscope® is the world's leading device used for oral cancer screening with 13,000 units sold and 25 million scans completed since the launch in 2006. The device is approved for sale in the United States, Canada and more than 20 other countries.

The tissue fluorescence visualization technology on which the VELscope is based was developed in partnership with the British Columbia Cancer Agency and is supported with more than $50 million in research provided by the National Institutes of Health and other leading institutions and universities.

Demand is fueled by a quantity of clinical data and recommendations from influential sources supporting use of the device as well as increased awareness of the dangers of oral cancer.

The company recently switched distributors in order to further expand their footprint, drive utilization and increase profitability. LED is also pursuing other complementary services and products including a recently launched pathology lab and development of a genetic oral cancer test.

Analyst Brian Marckx stated, "Despite their leading position, the market remains barely penetrated, offering significant upside opportunity. Applications for their technology into other cancers including skin and cervical provide potential market-expansion and additional growth opportunities."

The shares are currently trading at $0.50, well below Zacks' target of $2.00, and with 73 million shares outstanding, the company is capitalized at $36.5 million.

For more information, please visit the company's website www.ledmd.com. For more information about Zacks Small-Cap Research or to obtain their research, visit their website at www.zacks.com.

About InvestmentPitch

InvestmentPitch.com, a multimedia company that provides a combined solution for creating and hosting financial video content, and distributing it across multiple platforms to investors and financial professionals, specializes in producing corporate interviews and three minute videos based on news releases and research reports. Please visit InvestmentPitch.com and browse our extensive library of investment videos. For more information please call 604-684-5524.

CONTACT:
InvestmentPitch.com
Barry Morgan, CFO
604-684-5524
bmorgan@investmentpitch.com